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Abstract 
BACKGROUND: Chronic oedema care is patchy and of variable quality internationally.  
This study was undertaken to develop and evaluate a system of care that would provide 
for patients within a geographical area of London (Wandsworth), UK. 
METHODS AND RESULTS: A prospective cohort design with intervention of a new 
service design following a six month baseline period. Patients were identified through 
health professionals. A stratified random sample was drawn from all patients and an 
implementation strategy developed. Clinical assessment combined with questionnaires 
evaluated clinical, patient and health service outcomes at six monthly periods. 
In all, 312 patients were identified in community and acute services giving a crude 
ascertainment rate of 1.16 per 1,000 population. The random sample of 107 was mostly 
female (82%) with mean (SD) age of 72.9 (12.4) in men and 68.6 (15.0) years in 
women.  Mean reductions in limb volume achieved statistical differences at 6-12 months 
after implementation (difference [d] =115 ml, p=0.0001).  Incidence of cellulitis dropped 
from 41.5/ 100 patient years at baseline to zero at 6-12 months.  Quality of life showed 
greatest improvements between baseline and 6 months post implementation, the 
largest differences being in role physical (d=32.7, p=0.0001) and role emotion (d=24.0, 
p<0.0001).  Euroqol increased following implementation by a mean score of 0.05 
(p=0.007).  There was a in six monthly health care costs from £50171 per100 patients at 
baseline to £17618 between 6 and 12 months.   
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CONCLUSIONS: This process of implementation improves health outcomes whilst 
reducing healthcare costs in patients with lymphoedema. 
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Introduction 
Chronic oedema is considered common in the community but lymphoedema is 
considered rare yet both scientifically and clinically they should be considered one of 
the same.  Traditional teaching stated that 90% of interstitial fluid was reabsorbed by 
the venous capillaries but this is now disproved.  The recent revision of the Starling 
principle indicates that, in the steady state, there is a net but dwindling fluid filtration 
along the entire length of the blood capillary with all tissue fluid drained by the lymphatic 
[1, 2].  This places the lymphatic centre stage in tissue fluid homeostasis.  All chronic 
oedema represents lymphatic failure either because the lymphatic is primarily at fault or 
because the lymphatic is overwhelmed by an excessive lymph load (high microvascular 
fluid filtration). 
There is a tendency in clinical practice to pigeon-hole chronic oedema according to 
diagnosis eg heart failure, hypoproteinaemia, lymphoedema etc, rather than consider 
the underlying pathophysiology.  Most cases of chronic oedema seen in the community 
are compound.  For example poor lymph drainage in the lower limbs often arises from 
immobility and lymphatic damage from cellulitis or chronic fluid overload.  High 
microvascular fluid filtration (lymph load) results from chronic dependency (gravitational 
effects on venous pressure), heart failure, obesity (causing venous obstruction when 
sitting) or chronic venous disease with eventual permanent failure of lymph drainage in 
circumstances akin to chronic heart failure.  Therefore chronic oedema and 
lymphoedema should be considered equivalent and will subsequently be referred to as 
chronic oedema (CO) in this article.  Management should focus on improving lymph 
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drainage and normalising microvascular fluid filtration (lymph load). 
When severe, CO can be painful and disabling.  Because lymph drainage is important 
for trafficking of immune effector cells, CO predisposes to infection particularly cellulitis. 
[3, 4]  Cellulitis may be recurrent and difficult to control unless swelling is reduced. [3]    
Indeed many cases of recurrent cellulitis (erysipelas) may well result from a covert, pre-
existing lymphatic insufficiency [5].  A recent study of penicillin prophylaxis to prevent 
cellulitis demonstrated that CO was a major reason for treatment failure [6]. 
Major advances in lymphatic biology have revolutionised our understanding of the 
pathogenesis of lymphoedema.  The recent discovery of several causal genes indicates 
molecular mechanisms are likely to underlie many forms of primary CO [4].  Cancer 
treatment is perceived to be the dominant cause of CO but an epidemiological study 
revealed only a quarter of cases, at most, were cancer related [3].  Chronic oedema 
frequently occurs in patients with other chronic diseases such as obesity, heart failure, 
venous disease, arthritis and neurodisability eg spina bifida and stroke, where 
immobility and a lack of stimulus to lymph flow are major contributing factors. 
As yet there are no drug treatments to enhance lymph flow.  This may change as more 
molecular mechanisms controlling lymphatic function are discovered.  The first drug to 
be used for the treatment of breast cancer-related lymphedema is now in Phase 1 trials 
[4].  Diuretics are frequently prescribed but this class of drug does nothing to improve 
lymph flow and works by excreting salt and water so reducing microvascular fluid 
filtration.  Management of CO is directed at increasing lymph flow by Decongestive 
Lymphatic Therapy [Complex Decongestive Therapy (CDT) Comprehensive 
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Decongestive Physiotherapy (CDP)]  [7, 8, 9].  Decongestive Lymphatic Therapy utilises 
basic physiological principles of massage, movement and compression to enhance 
lymph flow. 
There is growing evidence on the epidemiology and provision of care for patients 
suffering from chronic oedema within the population. Most epidemiological studies in 
western countries have however focused on specific patient populations. As an 
example, more than one in five of women who undergo breast cancer treatment develop 
CO despite improvements in surgical technique[10]. There is little published information 
on the prevalence of non-cancer related CO in populations.  A UK study identified 
patients suffering from lymphoedema in a geographical population of 600,000 in South 
West London [3].  In total, 823 patients suffering from lymphoedema were identified 
through the health services, giving a crude rate of 1.33/1,000 population.  This is an 
underestimate as it does not take account of patients who are not accessing treatment.  
Even in those identified, one third had not been told they suffered from lymphoedema 
and 36% had received no treatment for this condition.  This methodology has been 
repeated more recently in an urban population of the East Midlands in the UK [11]. This 
cross sectional study was carried out in Derby City (UK) which has a population of 
approximately 247,100.   Data were obtained from ten sources, namely:  the in-patients 
of one acute and one community hospital, one specialist and three non-specialist out-
patient clinics (dermatology, plastic surgery and diabetic foot clinic), all community 
nursing services, general practices (n=41) and nursing/residential homes (n=26) in the 
catchment area. Within the study population of Derby City residents, 971 patients were 
identified with chronic oedema (estimated crude prevalence 3.93 per 1,000, 95% CI 
7 
 
3.69-4.19).  The prevalence was highest amongst those aged 85 or above (28.75 per 
1,000) and was higher amongst women (5.37 per 1,000) than men (2.48 per 1,000).  
The prevalence amongst hospital in-patients was 28.5%. Only 5 (3%) patients in the 
community population had oedema related to cancer or cancer treatment.  Of the 304 
patients identified with oedema from the Derby hospitals or community health services 
121 (40%) had a concurrent leg ulcer. There is a paucity of professional knowledge and 
information about CO with general agreement that the provision of care is inadequate 
[12].  
 
 The Lymphoedema Support Network (LSN) the UK national patient support group has 
identified large deficits in service provision, with many parts of the country failing to offer 
services [13]. This has led to poor access with patients forced to travel long distances to 
specialist centres rather than receiving care locally.  Where care is provided, it is often 
delivered through acute specialist or palliative care centres.  Major problems of access 
and discontinuity of care arise across the country.  
The evidence base supporting treatment of CO is poor and has been confirmed in a 
number of systematic reviews [14, 15]. This may in part reflect the low profile of CO as a 
health care problem with little investment in research other than in the breast cancer 
field.  This creates a challenge for any project that aims to provide patients with the best 
standard of care.   
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In 2002 the King’s Fund awarded a grant to develop and evaluate a model of care for 
patients with all forms of chronic oedema [16]. The aim of this project was to develop, 
implement and evaluate health service and patient outcomes using an appropriate 
model of care within a London-based PCT and to use these results to develop 
recommendations for national care provision.  The results of this community service 
implementation are now reported. 
Primary outcome measures were:-   
1) Quality of Life (QOL) 
2) Incidence of cellulitis 
3) Limb volumes 
Methods 
Service development 
Development of a Primary Care Trust Model within Wandsworth PCT 
The model of care developed reflected the shift from acute outpatient to community 
services where the emphasis was on healthy living, disease prevention and 
rehabilitation. The project involved a partnership with the Lymphoedema Support 
Network (LSN) who participated in all aspects of the work including leading on the 
assessment of patient experience.  
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Community Hospital 
The hub of the service was located in the community hospital in order to provide access 
to a multi-disciplinary team, including physiotherapy and rehabilitation. The service was 
led by a clinical nurse specialist in CO management. The service was supported by two 
trained community nurses. The nurses participated in the hospital clinic that ran for one 
day a week, ensuring continuity of care between the hospital and community. These 
nurses were able to undertake more specialised treatment in patients’ homes and were 
able to arrange for patients to be seen by the specialist service if required. Patients 
were able to access the service by a number of routes and extensive advertising of the 
service was undertaken as part of the implementation strategy.  
 
 
 
Shared care model 
A model of shared care was used for the many immobile, housebound patients. The 
specialist nurse visited at home with the community nurses to advise on treatment and, 
where necessary, refer patients to the hospital-based service for further investigation 
and treatment. Intensive treatment could be provided by the specialist nurse to 
housebound patients if required. This included a period of daily bandaging with exercise 
and skin care. Community nurses were supported during the transition of patients to 
long-term management in order to ensure that the progress that had been made during 
the intensive treatment episode was maintained. Increasing numbers of community 
nurses were able to take on more specialist aspects as their own knowledge and skills 
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developed. The community link nurses were also used to monitor treatment initiated in 
the clinic and support local staff in long-term management. The specialist nurse was 
also able to use key practice nurses to continue to prescribe garments and assist in 
long-term management with stable patients. 
 
Inclusion of Chronic Oedema within the Drug Tariff 
A major challenge for the project was the provision of appropriate compression and 
other materials for treatment. At the outset of the project specialist garments and 
materials were only available through hospital based services where they existed. Many 
patients had no access to these. The work of the Lymphoedema Framework, of which 
this project was integral, led to a change in the UK drug tariff in March 2006. At this time 
the recommendations from the project led to the availability of products through GP and 
nurse prescribing. In order to facilitate this change, links with a number of key 
pharmacists across the Trust were made.  
 
Development of the Best Practice for the Management of Lymphoedema  
A key objective of the project was to determine the best practice for the diagnosis and 
treatment of patients with chronic oedema and lymphoedema. A best practice document 
was developed following the systematic reviews and adopted the HTA consensus 
methodology [7]. This involved an international panel of expert reviewers. This document 
has now been adopted internationally. 
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Study Design 
The project was undertaken within Wandsworth Primary Care Trust (population 268,000).  
The overall design used a number of implementation methods to support a three-stage 
study comprising pre-implementation, service development and post-implementation 
evaluation.  Patients were followed up throughout these stages. 
Patients were evaluated using the outcome measures at entry into the study (study entry 
– visit 1) and after a period of 6 months (baseline – visit 2) before implementation of 
treatment and at 6 (visit 3) and 12 (visit 4) months after implementation of treatment. 
Evaluation methods 
These were established by the outcomes working group.  This was a multi-disciplinary 
team, including patients, health care professionals and researchers.  Their remit was to 
design a data collection tool that would allow for the evaluation of health service and 
patients outcomes.  The design of the study involved two methods.  Firstly patients were 
identified through health care professionals within the trust.  Secondly, patients were 
evaluated in a pre versus post implementation model.  Initially an RCT was considered 
for this project.  However, concerns were raised about restrictions that such designs 
would be placed on attempting to treat all patients and the possible contamination that 
would be experienced by randomising patients within a single service, either 
individually, or as clusters.  The pre implementation period allowed for patients to be 
followed up during their normal treatment regimen, and using this design each patient 
acted as their own control. 
Patient Assessment 
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The identification of patients followed the methods used in a previous study in south 
west London [3].Briefly, this involved contacting all relevant health care professionals 
within the catchment area, to identify all patients they were aware of currently suffering 
from chronic oedema.  This was defined as chronic swelling present for more than 3 
months, not responding to diuretic therapy or elevation, irrespective of the underlying 
aetiology [2].  The aim of this was to identify all patients who would require treatment 
irrespective of their current level of care. 
Following identification, a random sample was drawn from this patient population to 
allow for a more detailed examination and interview.   
Patients were contacted through a letter from their GP, and followed up by a research 
nurse.  Interviews took place according to the patient’s wishes, either in a clinical area 
or within the patient’s own home.  The interviews took place at six monthly intervals, two 
being undertaken prior to patients starting treatment within the new service ie visit 1 and 
2.  This allowed for an examination of the baseline (current) treatment and outcomes 
prior to entering the new service.   
  Outcome measures 
At each six monthly visit patients completed a questionnaire.  This consisted of a 
number of sections specific to the condition, and generic tools used to evaluate quality 
of life (SF-36) [17, 18], pain (SF-MPQ)[19] and health status (Euroqol EQ-5D) [20].    
Generic tools were used to determine health related quality of life. More recent studies 
have since developed and validated disease specific tools.  The McGill pain 
questionnaire (SF-MPQ) was included because a previous study had indicated that pain 
13 
 
was a greater problem than had previously been reported [3].  Euroqol was chosen to 
provide evidence of health status at different time points in order that an evaluation of 
changes in health status could be made. 
Training was given to the four research nurses who undertook the evaluation of 
patients, to ensure consistency and repeatability. Limb volume measurements were 
made using a standard procedure as recommended by the Best Practice document [7].  
Complications such as the development of infection (cellulitis) were recorded at each six 
monthly visit.  Costs were assessed by interviewing patients about their use of health 
services over the previous six months. These data were combined with estimated unit 
costs of care derived from the British National Formulary [21], Drug Tariff [22], Unit 
costs [23] and NHS reference costs [24]. 
Statistical methods 
Sample size. The number of patients recruited into this study was not undertaken 
according to a pre-defined effect size, due to the uncertainties surrounding the potential 
changes in key parameters.  The random sample was however, a reflection of the total 
patient group identified in this study. 
Analysis was undertaken using quantitative methods.  For continuous data this was 
undertaken using matched t-test analysis.  This was chosen in order to determine 
whether and when a step change in outcomes occurred.  
The study was supported by a steering group of relevant experts including patients and 
carers. The data collection tools were piloted and amended with 5 patients prior to 
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adaption and use. Ethical approval was obtained from the local Independent Ethics 
Committee. The study was performed in accordance with the guidelines of the 
Declaration of Helsinki (47), and the principles of Good Clinical Practice (GCP) ICH E6 
and EN540 standards (48). 
 
Results 
Case Identification and Prevalence Estimates 
In all, 327 patients were identified in community and acute services and were resident 
within Wandsworth PCT (population 267,943).  Of these, 15 had swelling that resolved 
overnight and were excluded as they did not meet the criteria for chronic oedema set by 
this study.  Of the total, 257 (82.4%) were women.  This gave a crude ascertainment 
rate of 1.16 per 1,000 population.  As expected, the ascertainment was highly age 
dependent with patients over the age of 85 years having the highest risk of chronic 
swelling.  Women suffered to a greater extent than men, with crude ascertainment rates 
of 1.87 and 0.42 respectively per 1,000 population.  
The site of swelling was also highly related to the patients’ gender. While less than 10% 
of men suffered from arm swelling (4/55), this accounted for 40% of all women (99/257).  
Leg swelling was age dependent for both men and women, being more prevalent in the 
older groups.  Women still experienced greater problems with leg swelling, with crude 
prevalence of 0.92/1,000 versus 0.39/1,000 in men.  Of the total, only 112 (35.9%) had 
swelling related to a cancer diagnosis.   
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From this ascertainment study 204/256 (79.7%) were receiving some form of care for 
their CO. Most patients had received skin care advice from their health professional, 
together with exercise advice and elastic hosiery.  Relatively few (10.8%) had received 
bandaging for their CO, but 13.8% had received bandaging for concurrent leg 
ulceration.  Chronic oedema bandaging involves adaption of the technique to include 
the toes and thighs [7] whereas community leg ulcer bandaging protocols are below 
knee with no toe bandaging.  Both manual lymph drainage (4.4%) and self massage 
(6.4%) were rarely used.  Diuretics had been used in 16.3% despite these being 
generally contra-indicated in lymphoedema management, except in patients with 
oedema where salt and water overload occurs. 
 
Cross Sectional Analysis of Patient Sample 
107 patients were randomly selected from the original 312 for further evaluation [Table 
I].  Swelling had been present for over 10 years in 50(47.2%), 1-9 years in 54(50.9%) 
and in less than one year in only 2 patients. 
Over the duration of the swelling 52/103 (50%) had experienced at least one acute 
episode of cellulitis.  Of these, 17 (32.6%) had required hospitalisation at least once for 
this infection.  In all, 21/106 (19.8%) had experienced an acute infection within the past 
year, with five (23.8%) of these requiring admission to hospital [Table II].  
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Clinical results of treatment 
1. Health Related Quality of Life 
a. SF-36 
Major improvements in the SF-36 scores occurred during treatment within the new 
service [Table III].   
Significant improvements were identified in most HRQOL domains post-implementation 
(between visits 2 and 3), but particularly role physical (difference [d] =32.7) and role 
emotional (d=24.0) both of which achieved a level of significance of p<0.0001. 
Analysis between six months and one year (between visits 3 and 4) indicated further 
improvements in bodily pain, vitality, social functioning and mental health although the 
magnitude of change was smaller than that experienced within the first 6 months 
(d<10.0). 
No significant changes were seen during the run-in pre-implementation period except in 
role physical where it was considered contact with and encouragement from the health 
care professionals may have been responsible (d=15.5, p<0.001). None of the 
differences above appeared to be influenced by the presence (or healing of) the 
concurrent leg ulceration (results not shown) 
b. SF-MPQ 
Pain scores improved significantly post-implementation and continued to improve from 6 
months to 1 year as given by negative differences of -2.1 and -0.5 respectively (table 
III). There was little change in pain scores between study entry and baseline ie before 
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treatment was implemented. 
c.EuroQol 
EuroQol measures physical, psychological and social dimensions of health that are 
influenced by the patient’s experiences, beliefs, expectations and perceptions.  There 
was noticeable consistency between scores pre-implementation and then significant 
improvements both during the first 6 months  post-implementation (d= 0.05) with further 
improvements from 6-12 months (mean difference 0.03)  [Table III]. In the sub-group 
who had concurrent ulceration,  the results were not confounded by the ulcer healing 
during follow-up. 
2. Incidence of cellulitis 
There was a significant reduction in both the rate of cellulitis (-34.7 infections per 100 
patient years) and the rate of admission for cellulitis (-5.6/100 patient years) between 
the 6 months pre-implementation and the 6 months post-implementation [Table IV].  
From 6 months to one year post-implementation there were no reported cases of 
cellulitis, despite continuous patient follow up.   
Reduction in swelling 
Patients with arm or leg CO experienced small but significant reductions in limb volume 
6-12 months post-implementation [Table V].  Mean volume reductions were 59 ml in 
patients with arm disease and 155 ml in patients with leg disease (both p<0.001). What 
was surprising was that no substantial reductions in limb volumes occurred during the 
first 6 months post-implementation. Improvements in limb volume prior to 
18 
 
implementation may reflect improvements in mobility generated by encouragement from 
health care professionals. 
 
3. Cost and effectiveness of treatment 
The costs of care are presented in table VI. The costs are presented as a cost over a 
six month period for 100 patients, using the data collected during the study.  Overall 
costs reduced from £50171 prior to implementation to £27352 within the first 6 months 
and subsequently £17618 between 6 months and one year.  The results show that 
resources moved from the acute care setting to lower cost interventions in the 
community. Costs of bandaging for swelling increased with a reduction in costs for ulcer 
bandaging. This is not too surprising as ulcer bandaging may be reduced due to healing 
of the ulcer.  However, the reduction in cost cannot be attributed merely to the reduction 
in numbers treated for ulceration.    Excluding the costs of ulcer bandaging reduces the 
costs of care to £25303, £23622 and £15710 respectively.  These changes are largely 
due to the shift from acute services and reduced frequency of bandaging for swelling 
following an initial rise. As expected hosiery costs increased as more patients were 
prescribed and fitted hosiery. The cost of care reduced substantially 6 months to one 
year after implementation.   
The overall effectiveness of the new service model is given by the change in utility 
scores as determined by EuroQol.  While there was no evidence of a change in utility 
during the baseline period (visits 1 and 2) there was evidence that following 
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implementation utility improved.  [Table III]. Reduced cost with improved health 
outcomes demonstrate the cost-effectiveness of the service. 
 
Discussion 
 
Chronic oedema and cellulitis, in particular, present an enormous challenge to health 
and social services in terms of both management and cost.  A scenario frequently arises 
where the development of lower limb oedema further compromises mobility.  Patients 
who are already infirm and overweight deteriorate further. 
One of the difficulties in the community is implementing whole limb compression.  
Community staff are trained for below knee compression therapy eg venous leg ulcers 
but not for toe, forefoot, thigh high or upper limb bandaging.  Such treatment is 
necessary in chronic oedema where standard below knee compression bandaging can 
make toe or thigh swelling worse.   
The results of this study have highlighted the potential benefits of developing a service 
model for chronic oedema that combines a specialist and generalist approach to care.  
It has shown clinical improvements in terms of reduction in limb volume and reduced 
complications particularly cellulitis. While the clinical benefits are key to determining the 
potential for any service development it is important to evaluate the benefits to patients 
in terms of their improved quality of life.  A recent case control study using the same 
cohort of patients has demonstrated that CO impacts on various aspects of quality of life 
but also on the ability of patients to cope with their condition and on their social support 
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[25]. Subgroups of the patient population may be impacted differently according to their 
clinical situation. As an example, non-cancer patients are more susceptible to 
developing cellulitis [26]. This analysis has not chosen to undertake subgroup analysis 
of the quality of life results due to the relatively small numbers and the potential for 
confounding factors to influence these outcomes. There is evidence that other 
interventions such as liposuction may offer patients benefits to their quality of life [27].   
The results of this study also show that the model of care leads to reduced cost of care.  
This was achieved by using largely existing resources through the development of staff 
expertise and appropriate referral and intervention when necessary.  Whilst much of the 
care remained in the community, support from specialist staff was essential when 
dealing with complex patients.  The model of shared care between specialist and 
community staff could have been a factor that resulted in the reduction in admissions 
and improved outcomes, together with a standard cellulitis policy in place.   
Cellulitis is the sixth most expensive emergency in the UK and is frequently recurrent as 
results here demonstrate [28].  Chronic oedema is one of the main risk factors for 
cellulitis [29].  Recent work has revealed that covert underlying lymph drainage 
abnormalities frequently initiate cellulitis [5].   Recurrent cellulitis can be prevented by 
prophylactic penicillin in the majority of cases but relapses once prophylaxis stops with 
compromised local immune competency related to chronic oedema a likely explanation 
[6].   
The work has shown that admissions to acute care following the development of 
cellulitis occur frequently.  The potential for reducing admissions is observed in this 
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study, and will have economic and patient benefits.  Reducing needless hospital 
admissions is a key priority for health services.  Clearly an effective prevention strategy 
and rapid intervention could prevent many hospitalisations.  Cellulitis may also 
contribute to the worsening of the CO, leading to a cycle of more severe swelling, and 
an increase in the incidence of cellulitis and more health service resource. 
A key aim of care is to identify patients at an early stage to prevent the development of 
complex disease due to neglect and prevent complications such as infection and 
immobility.  This study was based on patients already identified by healthcare 
professionals.  As the service develops it would be expected that early intervention and 
prevention would feature more prominently in the aims of the service.  Moreover, raising 
awareness and clear referral pathways would encourage these to occur.   
 
This study has a number of limitations. The sample size, although reflective of the larger 
population, is relatively small. Despite this fact there is evidence that they are typical of 
the types seen in current CO services in the UK [3, 11]. Many have had their condition 
for a long duration and have not had an appropriate diagnosis or treatment leading to 
deterioration and morbidity. As there are no agreed coding systems or requirements to 
screen for CO in primary care it is likely that many with mild CO will not be identified and 
only become apparent when complications occur. The study used well validated generic 
HRQoL tools, however more recently disease specific tools have been developed that 
may be more sensitive to change and should be incorporated into future research 
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[30,31]. Despite this the tools adopted for the study have been able to identify significant 
changes with appropriate interventions.  
While it is acknowledged that a number of patients did not complete all follow up visits, 
this reflects the complexity of the patient population. Of the 107 patients recruited to the 
study 21 did not complete the final assessment due to death (7), patients being unable 
or unwilling to continue (13) and one lost to follow up due to moving from the area. 
 
In summary, chronic oedema and cellulitis can be satisfactorily treated in the community 
providing the correct management strategy is implemented.  With the appropriate 
investment in community staff training and resources Decongestive Lymphatic Therapy 
can be cost effective with healthcare costs subsequently substantially reduced. 
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Table I.  Demographics and Details of 
Lymphoedema           n=107 
 
Age  mean (sd) 
Female 68.6 (15.0) 
Male 72.9 (12.4) 
  
Gender N (%) 
Female 88 (82.2) 
Male 19 (17.8) 
Family Unit 
Alone 42 (39.2) 
Partner 45 (42.0) 
Other relative 15 (14.0) 
Friend 1 (1.0) 
Other 4 (3.7) 
Housing Type 
Owner 58 (55.2) 
Council rented 21 (20.0) 
Private rented 13 (12.4) 
Sheltered housing 10 (9.5) 
Residential home 3 (2.9) 
Employment Status 
Retired 79 (73.8) 
Employed full time 12 (11.2) 
Not working, illness 5 (4.7) 
Employed part time 7 (6.5) 
Look after home 2 (1.9) 
Unemployed  0 - 
Other 2 (1.9) 
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Table II.  Details of Swelling 
Causes of Lymphoedema 
Primary 10 (9.6%) 
Secondary 94 (90.4%) 
   Infection 10 (10.6%) 
   Trauma & tissue damage: 
   cancer 
45 (47.8%) 
   Trauma & tissue damage:  
   non cancer 
8 (8.5%) 
   Malignancy 3 (3.2%) 
   Inflammation 3 (3.2%) 
   Phlebo-lymphoedema 17 (18.1%) 
   Immobility/dependency 7 (7.4%) 
  
Infections since start of swelling  
Never 51 (49.5%) 
Once 27 (26.2%) 
Twice 9 (8.7%) 
3-5 times 8 (7.8%) 
6-10 times 3 (2.9%) 
>11 times 5 (4.8%) 
Admissions for Infection since start of 
swelling 
Never 90 (84.1%) 
Once 10 (9.3%) 
Twice 5 (4.7%) 
3-5 times 2 (1.9%) 
Concurrent leg ulceration 
Yes 13 (12.1%) 
No 94 (87.9%) 
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Table III.  Health Related Quality of Life (SF-36 & Euroqol) at different visits. 
PF=physical functioning, RP=role physical, BP=bodily pain GH=general health 
Vi=vitality SF=social functioning RE= role emotional MH= mental health 
 
 Pre-implementation Post-Implementation 
 Visit 1 Visit 2 Visit 3 Visit 4 
 N Mean (sd) N Mean (sd) N Mean (sd) N Mean (sd) 
PF 107 45.9 (33.3) 96 45.9 (32.2) 86 48.8 (32.0) 83 49.9 (31.1) 
RP 107 50.6 (46.4) 95 67.4 (43.2) 86 98.5 (8.0) 83 98.5 (11.3) 
BP 107 64.0 (30.9) 97 67.3(28.8) 86 78.2 (21.4) 83 82.0 (17.8) 
GH 107 59.4 (26.1) 97 60.7 (24.6) 86 64.4 (24.6) 83 63.6 (25.4) 
Vi 107 51.5 (24.2) 97 52.7 (23.4) 86 64.4 (16.6) 83 68.6 (13.4) 
SF 107 66.7 (32.5) 97 71.4 (31.0) 86 82.7 (18.8) 83 89.4 (13.8) 
RE 107 66.4 (44.7) 97 77.3 (40.4) 86 99.6 (3.6) 83 98.8 (11.0) 
MH 107 73.2 (19.2) 97 75.4 (18.0) 86 81.1 (13.6) 83 85.0 (9.9) 
         
SF-MPQ 107 3.5 (6.3) 87 3.3 (5.9) 86 0.8 (2.1) 85 0.3 (1.1) 
         
Euroqol (EQ-5D) 103 0.66 (0.33) 93 0.66 (0.31) 86 0.71 (0.25) 82 0.73 (0.20) 
         
Changes in HRQoL between Visits (paired analysis) 
 Visit 1 & Visit 2 Visit 2 & Visit 3 Visit 3 & Visit 4 
 N Mean 
(95%CI) 
p- 
value 
N Mean 
(95%CI) 
p-
value 
N Mean 
(95%CI) 
p-
value 
PF 96 -0.6  
(-4.1, 2.8) 
0.71 86 2.9 
(-0.3, 6.1) 
0.073 83 0.8 
(-0.2, 1.8) 
0.10 
RP 95 15.5  
(7.7, 23.4) 
0.0002 86 32.7  
(23.3,42.2) 
0.0001 83 0 
(-2.8, 2.8) 
0.99 
BP 97 2.7 
(-1.7, 7.1) 
0.23 86 11.5 
(7.1,15.8) 
0.0001 83 4.4 
(1.9,6.9) 
0.0007 
GH 97 -0.6 
(-2.9, 1.8) 
0.64 86 3.0 
(0.3,5.8) 
0.030 83 -0.7 
(-2.2,0.8) 
0.35 
Vi 97 -0.5 
(-3.7, 2.6) 
0.73 86 11.5 
(8.1,14.8) 
0.0001 83 4.8 
(3.2,6.4) 
0.0001 
SF 97 3.4 
(-1.2, 8.0) 
0.15 86 11.6 
(6.6,16.5) 
0.0001 83 7.0 
(4.6,9.5) 
0.0001 
RE 97 8.6 
(-0.2,17.4) 
0.056 86 24.0 
(15.3,32.8) 
0.0001 83 -0.8 
(-3.3, 1.7) 
0.53 
MH 97 1.0 
(-1.6, 3.5) 
0.45 86 4.8 
(2.2, 7.4) 
0.0004 83 4.0 
(2.7, 5.4) 
0.0001 
          
SF-MPQ 97 -0.4         
(-1.1, 0.4) 
0.34 86 -2.1          
(-3.1, -1.1) 
0.0001 85 -0.5         
(-0.9, -0.2) 
0.005 
          
Euroqol (EQ-5D) 90 0.00 
(-0.03,0.04) 
0.93 83 0.05 
(0.01,0.08) 
0.007 82 0.03 
(0.00,0.05) 
0.031 
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Table IV.  Incidence of Cellulitis 
 Pre-implementation Post-implementation 
 Visit 1 Visit 2 Visit 3 Visit 4 
Rate of cellulitis 
Per  100 patient years 
41.5 14.9 6.8 0 
Rate of hospitalisation 
Per  100 patient years 
5.6 2.1 0 0 
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Table V.  Limb Volume Measurement of largest affected limb at different visits ( mls) 
Limb volume (mls) 
 Pre-implementation Post-implementation 
 Visit 1 Visit 2 Visit 3 Visit 4 
 N Mean (sd) N Mean (sd) N Mean (sd) N Mean (sd) 
Arm 42 2278 
(1048) 
37 2192 
(868) 
35 2214 
(904) 
35 2155 (869) 
Leg 64 4911 (3386) 51 4457 
(2946) 
51  4526 (3258) 49 4372 (3198) 
Total 106 3868  
(2997) 
88 3505 
(2562) 
86 3585 (2806) 84 3448  
(2726) 
Changes in Limb volume (mls) 
 Visit 1 & Visit 2 Visit 2 & Visit 3 Visit 3 & Visit 4 
 N Mean 
(95%CI) 
p-value N Mean 
(95%CI) 
p-
value 
N Mean 
(95%CI) 
p-value 
Change in arm 
volume  
37 122  
(-28,273) 
0.11 33 27  
(-41,95) 
0.43 35 59 
(31,86) 
0.0001 
Change in leg  
volume 
51 160  
(-159,478) 
0.32 45 49 
(-321,418) 
0.79 49 155 
(67,243) 
0.0009 
Change in volume 
(total) 
88 144  
(-48,336) 
0.14 78 39 
(-172,254) 
0.71 84 115 
(62,168) 
<0.0001 
 
 
 
